303752-38-7 Usage
Description
3-[(TERT-BUTOXYCARBONYL)AMINO]BICYCLO[1.1.1]PENTANE-1-CARBOXYLIC ACID, also known as 3-(Boc-amino)bicyclo[1.1.1]pentane-1-carboxylic Acid, is a chemical compound with a complex molecular structure. It is characterized by its bicyclic framework and a carboxylic acid group, which grants it unique chemical properties and potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
3-[(TERT-BUTOXYCARBONYL)AMINO]BICYCLO[1.1.1]PENTANE-1-CARBOXYLIC ACID is used as an intermediate for the preparation of heteroaryldihydropyrimidine derivatives. These derivatives are applied for the treatment of hepatitis B infections, offering a potential therapeutic solution to combat this viral disease.
Check Digit Verification of cas no
The CAS Registry Mumber 303752-38-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,3,7,5 and 2 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 303752-38:
(8*3)+(7*0)+(6*3)+(5*7)+(4*5)+(3*2)+(2*3)+(1*8)=117
117 % 10 = 7
So 303752-38-7 is a valid CAS Registry Number.
303752-38-7Relevant articles and documents
Large-Scale Synthesis and Modifications of Bicyclo[1.1.1]pentane-1,3-dicarboxylic Acid (BCP)
Ripenko, Vasyl,Vysochyn, Daniil,Klymov, Ivan,Zhersh, Serhii,Mykhailiuk, Pavel K.
, p. 14061 - 14068 (2021/07/20)
In flow photochemical addition of propellane to diacetyl allowed construction of the bicyclo[1.1.1]pentane (BCP) core in a 1 kg scale within 1 day. Haloform reaction of the formed diketone in batch afforded bicyclo[1.1.1]pentane-1,3-dicarboxylic acid in a
HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
-
, (2019/01/17)
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
COMPOUNDS, COMPOSITIONS AND METHODS
-
Paragraph 0218; 0325, (2019/02/25)
The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.